Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
J Ruwaard, MJ L’ Ami, EL Kneepkens, CLM Krieckaert, MT Nurmohamed, F Hooijberg, AWR van Kuijk, JC van Denderen, L Burgemeister, T Rispens, M Boers & GJ Wolbink. (2023) Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. Scandinavian Journal of Rheumatology 52:2, pages 129-136.
Read now
Read now
Eric Toussirot. (2019) Pharmacological management of axial spondyloarthritis in adults. Expert Opinion on Pharmacotherapy 20:12, pages 1483-1491.
Read now
Read now
Joaquín Borrás-Blasco, Antonio Gracia-Pérez, J Dolores Rosique-Robles, MD Elvira Casterá & F Javier Abad. (2014) Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Expert Opinion on Biological Therapy 14:2, pages 145-150.
Read now
Read now
José Miguel Senabre-Gallego, Carlos Santos-Ramírez, Gregorio Santos-Soler, Esteban Salas-Heredia, Mabel Sánchez-Barrioluengo, Xavier Barber & José Rosas. (2013) Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Preference and Adherence 7, pages 961-972.
Read now
Read now
Articles from other publishers (7)
Marleen Bouhuys, Willem S. Lexmond & Patrick F. van Rheenen. (2022) De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review. Biomedicines 10:5, pages 1034.
Crossref
Crossref
Hüseyin Turgut Elbek ÖZER. (2021) Remisyonda olan ankilozan spondilit hastasında tedavi kararı. Ege Tıp Dergisi, pages 49-52.
Crossref
Crossref
Ulf Lindström, Tor Olofsson, Sara Wedrén, Ilia Qirjazo & Johan Askling. (2019) Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Research & Therapy 21:1.
Crossref
Crossref
E. Yu. Loginova, T. V. Korotaeva, S. I. Glukhova & E. L. Nasonov. (2019) The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russian psoriatic arthritis registry). Rheumatology Science and Practice 57:5, pages 523-527.
Crossref
Crossref
A. V. Kundzer. (2019) Recommendations on the management of patients with axial spondyloarthritis. Proceedings of the National Academy of Sciences of Belarus, Medical series 16:1, pages 117-128.
Crossref
Crossref
Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Eugenio de Miguel, Alejandro Balsa, Emilio Martín-Mola, Daniel Seoane-Mato & Juan D. Cañete. (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology 55:7, pages 1188-1194.
Crossref
Crossref
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
473
494
.